MNPR - Monopar Therapeutics Inc

MNPR - Monopar Therapeutics Inc

https://www.monopartx.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting - Monopar Therapeutics ( NASDAQ:MNPR )

Benzinga • 1 day, 3 hours ago • score: 0.21

WILMETTE, Ill., Sept. 14, 2025 ( GLOBE NEWSWIRE ) -- Monopar Therapeutics Inc. ( "Monopar" or the "Company" ) MNPR, a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological ...

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

GlobeNewswire • 3 months ago • score: 0.19

WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 ( GLOBE NEWSWIRE ) -- Monopar Therapeutics Inc. ( "Monopar," the "Company," "us" and "our" ) ( Nasdaq: MNPR ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in ...

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers - Monopar Therapeutics ( NASDAQ:MNPR )

Benzinga • 3 months ago • score: 0.18

WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 ( GLOBE NEWSWIRE ) -- Monopar Therapeutics Inc. ( "Monopar," the "Company," "us" and "our" ) MNPR, a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with ...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

GlobeNewswire • 4 months, 2 weeks ago • score: 0.42

WILMETTE, Ill., April 29, 2025 ( GLOBE NEWSWIRE ) -- Monopar Therapeutics Inc. ( Nasdaq: MNPR ) , a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ...

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks Commentary • 8 months, 1 week ago • score: 0.43

Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.

52W High

$54.30

52W Low

$2.32

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.22

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.42

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

5.23

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

34.25%

Institutions (25–75% balanced)

51.77%

Shares Outstanding

6,170,000

Float

2,938,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.59%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

3.2074

Previous

2.5261

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025